← 產業報告目錄
India Thalassemia Market Research Report - Forecast to 2032
授權報價
| Single User Price | $2,950 USD |
| Multi User Licence (up to 10 users) | $3,950 USD |
| Enterprisewide Price (Global Site License) | $5,250 USD |
報告摘要
India Thalassemia Market Research Report Forecast to 2032
Market Overview
India Thalassemia Market is anticipated to register a CAGR of 5.19% during the review period. Thalassemia is a genetic blood condition in which the human body produces an abnormal kind of haemoglobin. It causes a huge number of blood cells to be destroyed, resulting in anaemia. Thalassemia is a genetic condition caused by the deletion or modification of a specific gene segment. If only one parent carries the gene, the child may get thalassemia mild. If both parents are chronic carriers, the child may acquire a severe version of the disease.
The growing government initiatives and support to raise awareness for thalassemia and the increased prevalence of thalassemia in India are major factors driving the growth of the Indian thalassemia market. However, the side effects associated with thalassemia drug treatment are expected to hamper the growth of the Indian market. Nevertheless, the advancements in prenatal and newborn screening technologies are anticipated to create lucrative opportunities for the players operating in the Indian market.
Market Segmentation
Based on type, the India thalassemia market has been bifurcated into alpha-thalassemia and beta-thalassemia.
On the basis of treatment & diagnosis, the India thalassemia market is segmented into treatment & diagnosis. diagnosis further segment into instruments and reagents.
Major Players
The key companies operating in India Thalassemia market are Cadila Pharmaceuticals, Centruion Remedies Private Limited, Agios Pharmaceuticals, Inc., Cipla Inc, Healing Pharma India Pvt. Ltd. (HPIPL), Rewine Pharmaceutical, Trexgen Pharmaceuticals Pvt. Ltd., Novartis AG, Bristol-Myers Squibb, and Sun Pharmaceutical Industries Ltd.
目錄 Table of Contents
TABLE OF CONTENTS
1 EXECUTIVE SUMMARY 13
2 MARKET INTRODUCTION 15
2.1 DEFINITION 15
2.2 SCOPE OF THE STUDY 15
2.3 RESEARCH OBJECTIVE 15
2.4 MARKET STRUCTURE 15
3 RESEARCH METHODOLOGY 16
3.1 OVERVIEW 16
3.2 DATA FLOW 18
3.2.1 Data Mining Process 18
3.3 PURCHASED DATABASE: 19
3.4 SECONDARY SOURCES: 20
3.4.1 Secondary Research data flow: 21
3.5 PRIMARY RESEARCH: 22
3.5.1 Primary Research DATA FLOW: 23
3.5.2 Primary Research: Number of Interviews conducted 24
3.6 APPROACHES FOR MARKET SIZE ESTIMATION: 24
3.6.1 Revenue Analysis Approach 24
3.7 DATA FORECASTING 25
3.7.1 Data forecasting Technique 25
3.8 DATA MODELLING 26
3.8.1 microeconomic factor analysis: 26
3.8.2 Data MODELLING: 27
3.9 TEAMS AND ANALYST CONTRIBUTION 29
4 MARKET DYNAMICS 31
4.1 INTRODUCTION 31
4.2 DRIVERS 32
4.2.1 Growing government initiatives and support to raise awareness for thalassemia 32
4.2.2 Increased prevalence of Thalassemia in india 32
4.3 RESTRAINTS 34
4.3.1 side effects associated with thalassemia drug treatment 34
4.4 OPPORTUNITY 35
4.4.1 Launch of services with Advancements in prenatal and newborn screening technologies 35
5 MARKET FACTOR ANALYSIS 36
5.1 PORTER'S FIVE FORCES MODEL 36
5.1.1 Threat of New Entrants 36
5.1.2 BARGAINING POWER OF SUPPLIERS 37
5.1.3 Threat of Substitutes 37
5.1.4 Bargaining Power of Buyers 37
5.1.5 Intensity of Rivalry 37
5.2 IMPACT OF COVID-19 ON THE INDIA THALASSEMIA MARKET 37
6 INDIA THALASSEMIA MARKET, BY TYPE 39
6.1 INTRODUCTION 39
7 INDIA THALASSEMIA MARKET, BY TREATMENT & DIAGNOSIS 42
7.1 INTRODUCTION 42
7.2 TREATMENT 44
7.3 DIAGNOSIS 44
8 COMPETITIVE LANDSCAPE 47
8.1 INTRODUCTION 47
8.2 MARKET SHARE ANALYSIS, 2022 47
8.3 COMPETITOR DASHBOARD 48
8.4 PUBLIC PLAYERS STOCK SUMMARY 50
8.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL 50
8.6 KEY DEVELOPMENTS & GROWTH STRATEGIES 51
8.6.1 Product Launch 51
9 COMPANY PROFILES 52
9.1 CADILA PHARMACEUTICALS 52
9.1.1 COMPANY OVERVIEW 52
9.1.2 FINANCIAL OVERVIEW 53
9.1.3 productS OFFERED 53
9.1.4 KEY DEVELOPMENTS 53
9.1.5 SWOT ANALYSIS 54
9.1.6 KEY STRATEGIES 54
9.2 AGIOS PHARMACEUTICALS, INC 55
9.2.1 COMPANY OVERVIEW 55
9.2.2 FINANCIAL OVERVIEW 56
9.2.3 products OFFERED 56
9.2.4 KEY DEVELOPMENTS 56
9.2.5 KEY STRATEGIES 57
9.3 CIPLA INC 58
9.3.1 COMPANY OVERVIEW 58
9.3.2 FINANCIAL OVERVIEW 59
9.3.3 productS OFFERED 59
9.3.4 KEY DEVELOPMENTS 59
9.3.5 KEY STRATEGIES 60
9.4 NOVARTIS AG 61
9.4.1 COMPANY OVERVIEW 61
9.4.2 FINANCIAL OVERVIEW 62
9.4.3 PRODUCTS OFFERED 62
9.4.4 KEY DEVELOPMENTS 63
9.4.5 SWOT ANALYSIS 63
9.4.6 KEY STRATEGIES 63
9.5 CENTURION REMEDIES PRIVATE LIMITED 64
9.5.1 COMPANY OVERVIEW 64
9.5.2 FINANCIAL OVERVIEW 64
9.5.3 Products OFFERed 64
9.5.4 KEY DEVELOPMENTS 64
9.5.5 KEY STRATEGIES 64
9.6 HEALING PHARMA INDIA PVT. LTD. 65
9.6.1 COMPANY OVERVIEW 65
9.6.2 FINANCIAL OVERVIEW 65
9.6.3 Products OFFERed 65
9.6.4 KEY DEVELOPMENTS 65
9.6.5 KEY STRATEGIES 65
9.7 REWINE PHARMACEUTICAL 66
9.7.1 COMPANY OVERVIEW 66
9.7.2 FINANCIAL OVERVIEW 66
9.7.3 Products OFFERed 66
9.7.4 KEY DEVELOPMENTS 66
9.7.5 KEY STRATEGIES 66
9.8 SUN PHARMACEUTICAL INDUSTRIES LTD. 67
9.8.1 COMPANY OVERVIEW 67
9.8.2 FINANCIAL OVERVIEW 68
9.8.3 PRODUCTS OFFERED 68
9.8.4 KEY DEVELOPMENTS 69
9.8.5 SWOT ANALYSIS 69
9.8.6 KEY STRATEGIES 69
9.9 BRISTOL-MYERS SQUIBB COMPANY 70
9.9.1 COMPANY OVERVIEW 70
9.9.2 FINANCIAL OVERVIEW 71
9.9.3 PRODUCTS OFFERED 71
9.9.4 KEY DEVELOPMENTS 71
9.9.5 SWOT ANALYSIS 72
9.9.6 KEY STRATEGIES 72
9.10 TREXGEN PHARMACEUTICALS PVT. LTD. 73
9.10.1 COMPANY OVERVIEW 73
9.10.2 FINANCIAL OVERVIEW 73
9.10.3 PRODUCTS OFFERED 73
9.10.4 KEY DEVELOPMENTS 74
9.10.5 KEY STRATEGIES 74
10 DATA CITATIONS 75
圖表清單 List of Tables & Figures
LIST OF TABLES
TABLE 1 QFD MODELLING FOR MARKET SHARE ASSESSMENT 27
TABLE 2 INDIA THALASSEMIA MARKET, BY TYPE, 2019–2032 (USD MILLION) 40
TABLE 3 INDIA THALASSEMIA MARKET, BY TREATMENT & DIAGNOSIS, 2019–2032 (USD MILLION) 43
TABLE 4 INDIA THALASSEMIA MARKET, FOR TREATMENT, BY TYPE 2019–2032 (USD MILLION ) 44
TABLE 5 INDIA THALASSEMIA MARKET, FOR DIAGNOSIS, BY TYPE 2019–2032 (USD MILLION) 44
TABLE 6 INDIA THALASSEMIA MARKET, FOR DIAGNOSIS, BY TYPE 2019–2032 (VOLUME UNITS) 44
TABLE 7 INDIA THALASSEMIA MARKET, FOR INSTRUMENTS, BY TYPE 2019–2032 (VOLUME UNITS) 45
TABLE 8 INDIA THALASSEMIA MARKET, FOR REAGENTS, BY TYPE 2019–2032 (VOLUME UNITS) 45
TABLE 9 PUBLIC PLAYERS STOCK SUMMARY 50
TABLE 10 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL 50
TABLE 11 PRODUCT LAUNCH 51
TABLE 12 CADILA PHARMACEUTICALS: PRODUCT OFFERED 53
TABLE 13 AGIOS PHARMACEUTICALS, INC: PRODUCT OFFERED 56
TABLE 14 AGIOS PHARMACEUTICALS, INC: KEY DEVELOPMENTS 56
TABLE 15 CIPLA INC: PRODUCT OFFERED 59
TABLE 16 NOVARTIS AG: PRODUCTS OFFERED 62
TABLE 17 CENTURION REMEDIES PRIVATE LIMITED: PRODUCTS OFFERED 64
TABLE 18 HEALING PHARMA INDIA PVT. LTD.: PRODUCTS OFFERED 65
TABLE 19 REWINE PHARMACEUTICAL: PRODUCTS OFFERED 66
TABLE 20 SUN PHARMACEUTICAL INDUSTRIES LTD.: FINANCIAL OVERVIEW 68
TABLE 21 SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS OFFERED 68
TABLE 22 BRISTOL-MYERS SQUIBB COMPANY: PRODCUTS OFFERED 71
TABLE 23 TREXGEN PHARMACEUTICALS PVT. LTD.: PRODUCTS OFFERED 73
LIST OF FIGURES
FIGURE 1 INDIA THALASSEMIA MARKET: STRUCTURE 15
FIGURE 2 INDIA THALASSEMIA MARKET REPORT: MARKET GROWTH FACTOR ANALYSIS (2022-2032) 31
FIGURE 3 DRIVER IMPACT ANALYSIS (2023-2032) 33
FIGURE 4 RESTRAINT IMPACT ANALYSIS (2022-2032) 34
FIGURE 5 PORTER'S FIVE FORCES ANALYSIS: INDIA THALASSEMIA MARKET 36
FIGURE 6 INDIA THALASSEMIA MARKET; TYPE SEGMENT ATTRACTIVENESS, (USD MILLION) 39
FIGURE 7 INDIA THALASSEMIA MARKET, BY TYPE, 2022 & 2032 (USD MILLION) 40
FIGURE 8 INDIA THALASSEMIA MARKET SHARE (%), BY TYPE, 2022 41
FIGURE 9 INDIA THALASSEMIA MARKET; TREATMENT SEGMENT ATTRACTIVENESS, (USD MILLION) 42
FIGURE 10 INDIA THALASSEMIA MARKET, BY TREATMENT, 2022 & 2032 (USD MILLION) 43
FIGURE 11 INDIA THALASSEMIA MARKET SHARE (%), BY TREATMENT & DIAGNOSIS, 2022 45
FIGURE 12 INDIA THALASSEMIA MARKET PLAYERS: COMPETITIVE ANALSIS, 2022 47
FIGURE 13 COMPETITOR DASHBOARD: INDIA THALASSEMIA MARKET 48
FIGURE 14 CADILA PHARMACEUTICALS: FINANCIAL OVERVIEW SNAPSHOT 53
FIGURE 15 CADILA PHARMACEUTICALS: SWOT ANALYSIS 54
FIGURE 16 AGIOS PHARMACEUTICALS, INC.: FINANCIAL OVERVIEW SNAPSHOT 56
FIGURE 17 CIPLA INC: FINANCIAL OVERVIEW SNAPSHOT 59
FIGURE 18 NOVARTIS AG: FINANCIAL OVERVIEW SNAPSHOT 62
FIGURE 19 NOVARTIS AG: SWOT ANALYSIS 63
FIGURE 20 SUN PHARMACEUTICAL INDUSTRIES LTD.: SWOT ANALYSIS 69
FIGURE 21 BRISTOL-MYERS SQUIBB COMPANY: FINANCIAL OVERVIEW 71
FIGURE 22 BRISTOL-MYERS SQUIBB COMPANY: SWOT ANALYSIS 72
提及公司
Cadila PharmaceuticalsCentruion Remedies Private LimitedAgios PharmaceuticalsInc.Cipla IncHealing Pharma India Pvt. Ltd. (HPIPL)Rewine PharmaceuticalTrexgen Pharmaceuticals Pvt. Ltd.Novartis AGBristol-Myers Squibband Sun Pharmaceutical Industries Ltd.
同分類最新報告（醫療與生命科學）
查看醫療與生命科學全部報告 →
量子訊息有限公司為 Market Research Future 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們